BTIG Initiates Buy on Zevra After $50M Portfolio Sale and Debt-Free Move
BTIG starts coverage on ZVRA with Buy rating and $23 target after Zevra sells SDX portfolio for $50 million and becomes debt-free.
/ 1659 items
#XY↓
Abivax Gets a $160 Boost: Jefferies Sees 'Differentiated' Obefazimod as UC Game-Changer
Jefferies starts Abivax coverage with Buy rating and $160 target. Views obefazimod as differentiated UC therapy; Q2 maintenance data de-risked for approval path.
ImmunityBio Builds the “World Bank of NK Cells”: 5 Billion Cancer-Fighting Cells from One Blood Draw in Just 12 Days
ImmunityBio just hit a huge milestone – they can now mass-produce and freeze powerful NK cells from healthy and cancer donors. One simple blood draw gives 8–10 ready-to-use doses.
Raymond James Upgrades Korro Bio to Outperform, Turns Bullish on Hyperammonemia Pivot
Raymond James upgrades Korro Bio to Outperform from Market Perform with $23 PT, bullish on pivot to hyperammonemia programs in UCDs & HE with strong preclinical data and high unmet need.
Immutep Halts Pivotal Lung Cancer Trial for Futility – Analysts Issue Sharp Downgrades
Immutep’s key Phase 3 trial for its cancer drug efti was stopped early due to poor results. Analysts from Citizens and Baird downgraded the stock.
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod 5 Pods
Insulet has launched a voluntary medical device correction for specific lots of Omnipod 5 Pods due to possible tubing issues. All other pods remain safe.